Results 291 to 300 of about 278,336 (309)

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy

Seminars in Cancer Biology, 2018
Frédéric Askin, Edward Gabrielson
exaly  

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology, 2015
Jun Hwee Kim, Julien Mazières, T de Pas   +2 more
exaly  

NSCLC

2008
openaire   +1 more source

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Journal of Thoracic Oncology, 2015
Shaodong Hong, Shiyang Kang, Jianhua Zhan   +2 more
exaly  

The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p

EBioMedicine, 2019
Xiaojing Wang, Yuanbing Shen
exaly  

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

Journal of Thoracic Oncology, 2019
Shun Lu, Yi Yang, Huajun Zheng
exaly  

miR-195 Targets HDGF to inhibit proliferation and invasion of NSCLC cells

Tumor Biology, 2014
Haizhou Guo
exaly  

Clinicopathologic Features of Advanced Squamous NSCLC

Journal of Thoracic Oncology, 2016
Silvia Novello, Suresh Ramalingam, Luis Paz-Ares   +2 more
exaly  

Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes

Journal of Thoracic Oncology, 2018
Hiroaki Satoh, Shingo Sakashita, Hidetoshi Yanai   +2 more
exaly  

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of Thoracic Oncology, 2018
Rosalyn Juergens, Naiyer A Rizvi, Matthew Hellmann   +2 more
exaly